Literature DB >> 20484716

The role of methylene blue in serotonin syndrome: a systematic review.

Bradley K W Ng1, Andrew J D Cameron.   

Abstract

BACKGROUND: A recent series of case reports has demonstrated a significant, previously unrecognized drug interaction between serotonin reuptake inhibitors (SRIs) and methylene blue (MB).
OBJECTIVE: The authors review the case reports and clinical audits relevant to this interaction and consider the diagnosis of serotonin syndrome in these cases.
METHOD: Articles were obtained from a systematic search of MEDLINE and PsychInfo databases, and from the bibliographies of relevant articles. Studies were considered relevant if the patient received MB and developed an acute confusional state, neuropsychiatric complications, or autonomic instability.
RESULTS: The review identified nine case reports and two retrospective reviews; 26 patients developed an acute confusional state after MB infusion; 24 of these patients were taking an SRI, and 1 was taking clomipramine. Serotonin syndrome was a possible diagnosis in all 25 of these patients.
CONCLUSION: SRIs can interact with MB, causing a serious adverse reaction consistent with serotonin syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484716     DOI: 10.1176/appi.psy.51.3.194

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  16 in total

1.  Response to methylene blue does not have to be considered only as rescue therapy for distributive shock.

Authors:  David H Jang; Lewis S Nelson; Robert S Hoffman
Journal:  J Med Toxicol       Date:  2013-12

Review 2.  Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review.

Authors:  Bina Tariq; Sorina R Simon; Walmari Pilz; Andra Maxim; Bernd Kremer; Laura W J Baijens
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-02       Impact factor: 2.503

3.  [Not Available].

Authors:  Annie Charbonneau
Journal:  Can J Hosp Pharm       Date:  2013-07

4.  Efficacy of methylene blue in an experimental model of calcium channel blocker-induced shock.

Authors:  David H Jang; Sean Donovan; Lewis S Nelson; Theodore C Bania; Robert S Hoffman; Jason Chu
Journal:  Ann Emerg Med       Date:  2014-10-23       Impact factor: 5.721

5.  Methylene blue inhibits function of the 5-HT transporter.

Authors:  Murat Oz; Dmytro Isaev; Dietrich E Lorke; Muhammed Hasan; Georg Petroianu; Toni S Shippenberg
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

6.  Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.

Authors:  M A Fox; M G Panessiti; P R Moya; T J Tolliver; K Chen; J C Shih; D L Murphy
Journal:  Pharmacogenomics J       Date:  2012-09-11       Impact factor: 3.550

7.  Revisiting the physiological effects of methylene blue as a treatment of cyanide intoxication.

Authors:  Philippe Haouzi; Maxime Gueguinou; Takashi Sonobe; Annick Judenherc-Haouzi; Nicole Tubbs; Mohamed Trebak; Joseph Cheung; Frederic Bouillaud
Journal:  Clin Toxicol (Phila)       Date:  2018-02-16       Impact factor: 4.467

8.  Antidotal effects of methylene blue against cyanide neurological toxicity: in vivo and in vitro studies.

Authors:  Philippe Haouzi; Marissa McCann; JuFang Wang; Xue-Qian Zhang; Jianliang Song; Ilker Sariyer; Diane Langford; Maryline Santerre; Nicole Tubbs; Annick Haouzi-Judenherc; Joseph Y Cheung
Journal:  Ann N Y Acad Sci       Date:  2020-05-06       Impact factor: 5.691

Review 9.  Methylene Blue Application to Lessen Pain: Its Analgesic Effect and Mechanism.

Authors:  Seung Won Lee; Hee Chul Han
Journal:  Front Neurosci       Date:  2021-05-17       Impact factor: 4.677

10.  Minimally invasive closed-chest ultrasound-guided substance delivery into the pericardial space in mice.

Authors:  S Laakmann; L Fortmüller; I Piccini; S Grote-Wessels; W Schmitz; G Breves; P Kirchhof; L Fabritz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-19       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.